Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.31 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548361 | 1.00 | FFAR2 (0.33) | FFAR2FFAR1PTGER4PTGER2UTS2R | |
| SCHEMBL12241692 | 0.90 | PPARG (0.35) | FFAR2TRPM8KMT2ATEAD1PPARG | |
| SCHEMBL2541351 | 0.84 | FFAR2 (0.33) | FFAR2FFAR1CTSAPDE2A | |
| SCHEMBL1743679 | 0.83 | GPR139 (0.35) | FFAR1PTGER4PTGER2UTS2RKMT2A | |
| SCHEMBL2548040 | 0.83 | GPR139 (0.35) | FFAR1PTGER4PTGER2UTS2RKMT2A | |
| SCHEMBL3706895 | 0.83 | GPR139 (0.35) | FFAR1PTGER4PTGER2UTS2RKMT2A | |
| SCHEMBL2541349 | 0.83 | TEAD1 (0.31) | FFAR2TEAD1 | |
| SCHEMBL2547011 | 0.81 | CDK2 (0.34) | FFAR1CTSACHRM5SLC6A3PPARG | |
| SCHEMBL3708146 | 0.81 | CDK2 (0.34) | FFAR1CTSACHRM5SLC6A3PPARG | |
| SCHEMBL2547009 | 0.81 | CDK2 (0.34) | FFAR1CTSACHRM5SLC6A3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | FFAR2 314/4885FFAR1 381/4885PTGER4 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.